Base de dados : MEDLINE
Pesquisa : F03.084.500 [Categoria DeCS]
Referências encontradas : 34796 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3480 ir para página                         

  1 / 34796 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29212505
[Au] Autor:Endres D; Huzly D; Dersch R; Stich O; Berger B; Schuchardt F; Perlov E; Venhoff N; Hellwig S; Fiebich BL; Erny D; Hottenrott T; Tebartz van Elst L
[Ad] Endereço:Section for Experimental Neuropsychiatry, Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. dominique.endres@uniklinik-freiburg.de.
[Ti] Título:Do patients with schizophreniform and bipolar disorders show an intrathecal, polyspecific, antiviral immune response? A pilot study.
[So] Source:Fluids Barriers CNS;14(1):34, 2017 Dec 07.
[Is] ISSN:2045-8118
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: We previously described inflammatory cerebrospinal fluid (CSF) alterations in a subgroup of patients with schizophreniform disorders and the synthesis of polyspecific intrathecal antibodies against different neurotropic infectious pathogens in some patients with bipolar disorders. Consequently, we have measured the prevalence of a positive MRZ reaction (MRZR)-a marker for a polyspecific, antiviral, intrathecal, humoral immune response composed of three antibody indices for the neurotropic viruses of measles (M), rubella (R), and varicella zoster (Z)-in these patients. METHODS: We analyzed paired CSF and serum samples of 39 schizophreniform and 39 bipolar patients. For comparison, we used a group of 48 patients with other inflammatory neurological disorders (OIND) and a cohort of 203 multiple sclerosis (MS) patients. RESULTS: We found a positive MRZR in two patients with schizophreniform disorders (5.1%); both suffered from schizodepressive disorders without any other signs suggestive of MS. None of the bipolar patients (0%) and four members of the OIND group (8.3%) showed a positive MRZR. In the MS cohort, a positive MRZR was found significantly more frequently [in 99 patients (48.8%)] than in the other patient groups (p > 0.001). In summary, we did not find a positive MRZR in a relevant subgroup of patients with schizophreniform or bipolar disorders. CONCLUSIONS: Our results indicate that the MRZR is highly specific to MS. Nevertheless, two schizodepressive patients also had a positive MRZR. This finding corresponds to the few MRZR-positive patients with OIND or other autoimmune disorders with central nervous involvement, implicating that the MRZR specificity for MS is high, but not 100%.
[Mh] Termos MeSH primário: Anticorpos Antivirais/líquido cefalorraquidiano
Transtorno Bipolar/imunologia
Transtornos Psicóticos/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Viral)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1186/s12987-017-0082-1


  2 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29345028
[Au] Autor:Goldberg JF
[Ad] Endereço:Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
[Ti] Título:Should we reserve big gun antimanic drugs for only big gun manias?
[So] Source:Bipolar Disord;20(1):7-8, 2018 02.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Mh] Termos MeSH primário: Antimaníacos
Transtorno Bipolar
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Antimanic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180119
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12597


  3 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214732
[Au] Autor:Van Rheenen TE
[Ad] Endereço:Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne, Melbourne, Australia.
[Ti] Título:Commentary on "Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force".
[So] Source:Bipolar Disord;20(1):72-73, 2018 02.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Mh] Termos MeSH primário: Comitês Consultivos
Transtorno Bipolar
[Mh] Termos MeSH secundário: Cognição
Transtornos Cognitivos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12577


  4 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29205721
[Au] Autor:Awad A; Cipriani A
[Ad] Endereço:Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.
[Ti] Título:Prophylactic mood stabilization: What is the evidence for lithium exposure in drinking water?
[So] Source:Bipolar Disord;19(7):601-602, 2017 11.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Mh] Termos MeSH primário: Água Potável/análise
Lítio/análise
[Mh] Termos MeSH secundário: Afeto
Transtorno Bipolar
Seres Humanos
Suicídio
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Nm] Nome de substância:
0 (Drinking Water); 9FN79X2M3F (Lithium)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12541


  5 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470928
[Au] Autor:Ganzola R; Nickson T; Bastin ME; Giles S; Macdonald A; Sussmann J; McIntosh AM; Whalley HC; Duchesne S
[Ad] Endereço:Institut universitaire en santé mentale de Québec, Québec City, Québec, Canada.
[Ti] Título:Longitudinal differences in white matter integrity in youth at high familial risk for bipolar disorder.
[So] Source:Bipolar Disord;19(3):158-167, 2017 May.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Previous neuroimaging studies have reported abnormalities in white matter (WM) pathways in subjects at high familial risk of mood disorders. In the current study, we examined the trajectory of these abnormalities during the early stages of illness development using longitudinal diffusion tensor imaging (DTI) data. METHODS: Subjects (16-28 years old) were recruited in the Scottish Bipolar Family Study, a prospective longitudinal study that has examined individuals at familial risk of mood disorder on three occasions, 2 years apart. The current study concerns imaging data from the first and second assessments. We analysed DTI data for 43 controls and 69 high-risk individuals who were further subdivided into a group of 53 high-risk subjects who remained well (high-risk well) and 16 who met diagnostic criteria for major depressive disorder (high-risk MDD) at follow-up. Longitudinal differences in fractional anisotropy (FA) between groups based on diagnostic status were investigated using the tract-based spatial statistics technique (TBSS). RESULTS: We found a significant reduction in FA (P <.05) across widespread brain regions over 2 years in all three groups. The trajectory of FA reduction did not differ significantly between groups. CONCLUSIONS: These results suggest that there are similar trajectories of FA reductions for controls and high-risk young adults, despite high-risk individuals being at a disadvantaged starting point considering their reduced WM integrity detected at baseline in previous studies. Difference in WM integrity between high-risk individuals and controls could therefore occur in earlier childhood and be a necessary but not sufficient condition to develop future mood disorders.
[Mh] Termos MeSH primário: Transtorno Bipolar
Substância Branca/diagnóstico por imagem
[Mh] Termos MeSH secundário: Adolescente
Adulto
Anisotropia
Transtorno Bipolar/diagnóstico
Transtorno Bipolar/epidemiologia
Transtorno Depressivo Maior/diagnóstico
Transtorno Depressivo Maior/epidemiologia
Imagem de Tensor de Difusão/métodos
Feminino
Seres Humanos
Estudos Longitudinais
Masculino
Anamnese/métodos
Neuroimagem/métodos
Estudos Prospectivos
Medição de Risco
Fatores de Risco
Escócia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12489


  6 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470892
[Au] Autor:Berk L; Hallam KT; Venugopal K; Lewis AJ; Austin DW; Kulkarni J; Dodd S; de Castella A; Fitzgerald PB; Berk M
[Ad] Endereço:Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Vic., Australia.
[Ti] Título:Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder.
[So] Source:Bipolar Disord;19(3):184-197, 2017 May.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Many people experience irritability when manic, hypomanic, or depressed, yet its impact on illness severity and quality of life in bipolar and schizoaffective disorders is poorly understood. This study aimed to examine the relationship between irritability and symptom burden, functioning, quality of life, social support, suicidality, and overall illness severity in a naturalistic cohort of people with bipolar I or schizoaffective disorder. METHODS: We used data from 239 adult outpatients with bipolar I or schizoaffective disorder in the Bipolar Comprehensive Outcomes Study (BCOS) - a non-interventional observational study with a 2-year follow-up period. Baseline demographic and clinical characteristics of participants with and without irritability were compared. A mixed-model repeated measures analysis was conducted to examine the longitudinal effect of irritability on clinical and quality-of-life variables over follow-up using significant baseline variables. RESULTS: At baseline, 54% of participants were irritable. Baseline irritability was associated with illness severity, mania, depression, psychotic symptoms, suicidality, poor functioning, and quality of life, but not diagnosis (schizoaffective/bipolar disorder). Participants with irritability were less likely to have a partner and perceived less adequate social support. On average, over follow-up, those with irritability reported more symptoms, functional impairment, and suicidality. Furthermore, the effects of irritability could not be fully explained by illness severity. CONCLUSIONS: Irritability was associated with more negative symptomatic, functional, and quality-of-life outcomes and suicidality. The identification, monitoring, and targeted treatment of irritability may be worth considering, to enhance health and wellbeing outcomes for adults with bipolar and schizoaffective disorders.
[Mh] Termos MeSH primário: Transtorno Bipolar
Humor Irritável
Transtornos Psicóticos
Qualidade de Vida
[Mh] Termos MeSH secundário: Atividades Cotidianas/psicologia
Adulto
Austrália/epidemiologia
Transtorno Bipolar/diagnóstico
Transtorno Bipolar/epidemiologia
Transtorno Bipolar/psicologia
Estudos de Coortes
Efeitos Psicossociais da Doença
Manual Diagnóstico e Estatístico de Transtornos Mentais
Feminino
Seres Humanos
Masculino
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)
Pacientes Ambulatoriais/psicologia
Transtornos Psicóticos/diagnóstico
Transtornos Psicóticos/epidemiologia
Transtornos Psicóticos/psicologia
Índice de Gravidade de Doença
Apoio Social
Ideação Suicida
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12486


  7 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28465388
[Au] Autor:Eagles JM
[Ad] Endereço:John M. Eagles, retired psychiatrist, Royal Cornhill Hospital, Aberdeen. Email: jmeagles@btinternet.com.
[Ti] Título:Bipolar affective disorder and childhood adversity: possible genetic links?
[So] Source:Br J Psychiatry;210(5):368, 2017 05.
[Is] ISSN:1472-1465
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Transtorno Bipolar
Acontecimentos que Mudam a Vida
[Mh] Termos MeSH secundário: Seres Humanos
Transtornos do Humor
[Pt] Tipo de publicação:LETTER; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1192/bjp.210.5.368a


  8 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28463343
[Au] Autor:Correll CU; Yu X; Xiang Y; Kane JM; Masand P
[Ti] Título:Biological treatment of acute agitation or aggression with schizophrenia or bipolar disorder in the inpatient setting.
[So] Source:Ann Clin Psychiatry;29(2):92-107, 2017 05.
[Is] ISSN:1547-3325
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Schizophrenia and bipolar disorders are chronic illnesses that commonly present with symptoms of acute agitation and aggression. These symptoms must be managed rapidly to prevent potential harm to the patient and others, including their caregivers, peers, and health care workers. A number of treatment options are available to clinicians to manage acute agitation and aggression, including non-pharmacologic behavioral and environmental de-escalation strategies, as well as biological treatment options such as pharmacologic agents and electroconvulsive therapy. We summarize the available biological treatment options for patients with schizophrenia or bipolar disorder presenting with acute agitation or aggression in the inpatient setting, focusing on antipsychotics. METHODS: The following searches were used in PubMed to obtain the most relevant advances in treating schizophrenia or bipolar disorder with acute agitation and aggression: (agitation, agitated, aggression, aggressive, hostile, hostility, violent, or violence) and (schizophr*, psychosis, psychot*, psychos*, mania, manic, or bipolar) and (*pharmacologic, antipsychotic*, neuroleptic*, antiepileptic*, anti-seizure*, mood stabilizer*, lithium, benzodiazepine*, beta blocker, beta-blocker, alpha2, alpha-2, *histamine*, electroconvulsive, ECT, shock, or transcranial). Individual searches were performed for each drug class. The studies were limited to peer-reviewed, English-language, and human studies. Most were placebo-controlled randomized controlled trials (RCTs) or meta-analyses. RESULTS: Among pharmacologic agents, antipsychotics, benzodiazepines, anticonvulsants, and lithium have been studied in randomized trials. Some typical and, more recently, atypical antipsychotics are available as both oral and short-acting intramuscular (IM) formulations, with 1 typical antipsychotic also available as an inhalable formulation. CONCLUSIONS: Among the pharmacologic agents studied in RCTs, atypical antipsychotics have the best evidence to support efficacy both in oral and short-acting IM formulations, as well as in one instance in an inhalable formulation.
[Mh] Termos MeSH primário: Transtorno Bipolar
Agitação Psicomotora/terapia
Psicotrópicos/farmacologia
Esquizofrenia/terapia
[Mh] Termos MeSH secundário: Agressão/efeitos dos fármacos
Agressão/psicologia
Transtorno Bipolar/psicologia
Transtorno Bipolar/terapia
Eletroconvulsoterapia/métodos
Serviços de Emergência Psiquiátrica/métodos
Seres Humanos
Agitação Psicomotora/psicologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Psicologia do Esquizofrênico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Psychotropic Drugs)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  9 / 34796 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28452409
[Au] Autor:Grunebaum MF; Ellis SP; Keilp JG; Moitra VK; Cooper TB; Marver JE; Burke AK; Milak MS; Sublette ME; Oquendo MA; Mann JJ
[Ad] Endereço:Molecular Imaging and Neuropathology Division, Department of Psychiatry, Columbia University Medical Center (CUMC) and New York State Psychiatric Institute, New York, NY, USA.
[Ti] Título:Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial.
[So] Source:Bipolar Disord;19(3):176-183, 2017 May.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate feasibility and effects of a sub-anesthetic infusion dose of ketamine versus midazolam on suicidal ideation in bipolar depression. Neurocognitive, blood and saliva biomarkers were explored. METHODS: Sixteen participants with bipolar depression and a Scale for Suicidal Ideation (SSI) score of ≥4 were randomized to ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg). Current pharmacotherapy was maintained excluding benzodiazepines within 24 hours. The primary clinical outcome was SSI score on day 1 post-infusion. RESULTS: Results supported feasibility. Mean reduction of SSI after ketamine infusion was almost 6 points greater than after midazolam, although this was not statistically significant (estimate=5.84, SE=3.01, t=1.94, P=.074, 95% confidence interval ([CI)]=-0.65 to 12.31). The number needed to treat for response (SSI <4 and at least 50% below baseline) was 2.2, and for remission (SSI=0) was 3.2. The strongest neurocognitive correlation was between memory improvement on the Selective Reminding Test (SRT) and reduction in SSI score on day 1 after ketamine (ρ=-.89, P=.007). Pre- to post-infusion decrease in serum brain derived neurotrophic factor (BDNF) correlated with reduction in SSI from baseline to day 1 after ketamine (n=5, ρ=0.90, P=.037) but not midazolam (P=.087). CONCLUSIONS: The study demonstrated feasibility. Suicidal thoughts were lower after ketamine than after midazolam at a trend level of significance, likely due to the small pilot sample. Memory improvement and BDNF are promising biomarkers. Replication is needed in an adequately powered full-scale trial.
[Mh] Termos MeSH primário: Transtorno Bipolar
Ketamina
Memória/efeitos dos fármacos
Midazolam
Ideação Suicida
[Mh] Termos MeSH secundário: Adulto
Anestésicos Dissociativos/administração & dosagem
Anestésicos Dissociativos/efeitos adversos
Biomarcadores/análise
Transtorno Bipolar/diagnóstico
Transtorno Bipolar/tratamento farmacológico
Transtorno Bipolar/psicologia
Fator Neurotrófico Derivado do Encéfalo/análise
Relação Dose-Resposta a Droga
Método Duplo-Cego
Monitoramento de Medicamentos/métodos
Feminino
Moduladores GABAérgicos/administração & dosagem
Moduladores GABAérgicos/efeitos adversos
Seres Humanos
Ketamina/administração & dosagem
Ketamina/efeitos adversos
Masculino
Midazolam/administração & dosagem
Midazolam/efeitos adversos
Meia-Idade
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anesthetics, Dissociative); 0 (Biomarkers); 0 (Brain-Derived Neurotrophic Factor); 0 (GABA Modulators); 0 (brain-derived neurotrophic factor, human); 690G0D6V8H (Ketamine); R60L0SM5BC (Midazolam)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12487


  10 / 34796 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468274
[Au] Autor:Charrier A; Olliac B; Roubertoux P; Tordjman S
[Ad] Endereço:Pôle Hospitalo-Universitaire de Psychiatrie de l'Enfant et de l'Adolescent (PHUPEA), Université de Rennes 1, Centre Hospitalier Guillaume-Régnier, 154 Rue de Châtillon, Rennes 35000, France. a.charrier@ch-guillaumeregnier.fr.
[Ti] Título:Clock Genes and Altered Sleep-Wake Rhythms: Their Role in the Development of Psychiatric Disorders.
[So] Source:Int J Mol Sci;18(5), 2017 Apr 29.
[Is] ISSN:1422-0067
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:In mammals, the circadian clocks network (central and peripheral oscillators) controls circadian rhythms and orchestrates the expression of a range of downstream genes, allowing the organism to anticipate and adapt to environmental changes. Beyond their role in circadian rhythms, several studies have highlighted that circadian clock genes may have a more widespread physiological effect on cognition, mood, and reward-related behaviors. Furthermore, single nucleotide polymorphisms in core circadian clock genes have been associated with psychiatric disorders (such as autism spectrum disorder, schizophrenia, anxiety disorders, major depressive disorder, bipolar disorder, and attention deficit hyperactivity disorder). However, the underlying mechanisms of these associations remain to be ascertained and the cause-effect relationships are not clearly established. The objective of this article is to clarify the role of clock genes and altered sleep-wake rhythms in the development of psychiatric disorders (sleep problems are often observed at early onset of psychiatric disorders). First, the molecular mechanisms of circadian rhythms are described. Then, the relationships between disrupted circadian rhythms, including sleep-wake rhythms, and psychiatric disorders are discussed. Further research may open interesting perspectives with promising avenues for early detection and therapeutic intervention in psychiatric disorders.
[Mh] Termos MeSH primário: Relógios Circadianos
Peptídeos e Proteínas de Sinalização do Ritmo Circadiano/genética
Ritmo Circadiano
Transtornos Mentais/genética
Transtornos do Sono-Vigília/genética
Sono
Vigília
[Mh] Termos MeSH secundário: Animais
Transtorno do Espectro Autista/etiologia
Transtorno do Espectro Autista/genética
Transtorno Bipolar/etiologia
Transtorno Bipolar/genética
Transtorno Depressivo Maior/etiologia
Transtorno Depressivo Maior/genética
Seres Humanos
Transtornos Mentais/etiologia
Esquizofrenia/etiologia
Esquizofrenia/genética
Transtornos do Sono-Vigília/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Circadian Rhythm Signaling Peptides and Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE



página 1 de 3480 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde